The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy
Australian Journal of Chemistry · 22.02.2022 · 75 (2) · 65-88
DOI: 10.1071/ch21184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian Journal of Chemistry, online erschienen am 07.12.2021. Verfasst von Melyssa L. Grieve und 1 weiteren Autor:innen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Several radiometals are of interest in the development of new a-emitting radiopharmaceuticals. This review highlights the role of coordination chemistry in the design of 225Ac, 212/213Bi, 212Pb, 149Tb, 227Th, and 223/224Ra radiopharmaceuticals to treat cancer. Several chelators have recently been developed that are addressing the specific requirements of each radiometal to provide outstanding radiolabelling and in vivo properties. These advances are supporting the momentum that is building around radiopharmaceuticals for targeted a therapy.
Zitieren
APA
Grieve, M. L., & Paterson, B. M. (2022). The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy. Australian Journal of Chemistry, 75(2), 65-88. https://doi.org/10.1071/ch21184
Vancouver
Grieve ML, Paterson BM. The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy. Australian Journal of Chemistry. 2022;75(2):65-88. doi:10.1071/ch21184
BibTeX
@article{Grieve2022,
author = {Grieve, Melyssa L. and Paterson, Brett M.},
title = {The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy},
journal = {Australian Journal of Chemistry},
year = {2022},
volume = {75},
number = {2},
pages = {65--88},
doi = {10.1071/ch21184}
}
EUVIMED